Jefferies Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Jefferies Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-504	Closed	-$9	–	1669
2020 Q2	$9	Buy	504 +391	+346%	+$5.44K	﹤0.01%	1202
2020 Q1	$1K	Buy	+113	New	+$1.41K	﹤0.01%	1985
2019 Q4	–	Sell	-101,309	Closed	-$2.72M	–	3228
2019 Q3	$2.72M	Sell	101,309 -112,133	-53%	-$3.15M	0.02%	887
2019 Q2	$5.79M	Buy	213,442 +69,900	+49%	+$2.19M	0.04%	403
2019 Q1	$4.98M	Sell	143,542 -90,058	-39%	-$2.6M	0.04%	446
2018 Q4	$4.56M	Buy	233,600 +230,800	+8,243%	+$4.75M	0.04%	457
2018 Q3	$75K	Buy	+2,800	New	+$91.4K	﹤0.01%	2255

Jefferies Group's PTLA Position: Q3 2020 in Review

Jefferies Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 504 shares — an estimated $9 sold.

Jefferies Group first reported a position in PTLA in Q3 2018 and held it in 7 quarters. The position peaked at $5.79M in Q2 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Jefferies Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Jefferies Group sold 504 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $9.
Jefferies Group first reported a position in Portola Pharmaceuticals, Inc. in Q3 2018 and held it in 7 quarters.
Jefferies Group's Portola Pharmaceuticals, Inc. position peaked at $5.79M in Q2 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.